{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:38:32Z","timestamp":1648903112766},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.2515\/therapie\/2010057","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T13:35:52Z","timestamp":1291988152000},"page":"423-428","source":"Crossref","is-referenced-by-count":0,"title":["La maladie d\u2019Alzheimer : comment \u00e9valuer l\u2019impact de la pathologie et des m\u00e9dicaments ?"],"prefix":"10.1016","volume":"65","author":[{"given":"Julien","family":"Delrieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010057_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers definitions working group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010057_bb0010","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12603-009-0047-4","article-title":"Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer\u2019s disease: the ALZHEMED (tramiprosate) experience","volume":"13","author":"Saumier","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.2515\/therapie\/2010057_bb0015","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010057_bb0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mildto-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebocontrolled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010057_bb0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(06)70677-9","article-title":"Disease-modifying trials in Alzheimer\u2019s disease: a European task force consensus","volume":"6","author":"Vellas","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2010057_bb0030","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2010057_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12603-009-0044-7","article-title":"What we have learned from the Myriad trials","volume":"13","author":"Hendrix","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.2515\/therapie\/2010057_bb0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0197-4580(03)00002-2","article-title":"Biological markers for therapeutic trials in Alzheimer\u2019s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer\u2019s disease","volume":"24","author":"Frank","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.2515\/therapie\/2010057_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuroimage.2008.07.003","article-title":"Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer\u2019s disease mild cognitive impairment, and elderly controls","volume":"43","author":"Morra","year":"2008","journal-title":"Neuroimage"},{"key":"10.2515\/therapie\/2010057_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.2009.04947.x","article-title":"Biomarkers in Alzheimer\u2019s disease: not yet surrogate endpoints","volume":"1180","author":"Coley","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.2515\/therapie\/2010057_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12603-009-0045-6","article-title":"What we have learned from the Xaliproden Sanofi-Aventis trials","volume":"13","author":"Douillet","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.2515\/therapie\/2010057_bb0060","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/brain\/awn146","article-title":"Ventricular enlargement as a possible measure of Alzheimer\u2019s disease progression validated using the Alzheimer\u2019s disease neuroimaging initiative database","volume":"131","author":"Nestor","year":"2008","journal-title":"Brain"},{"key":"10.2515\/therapie\/2010057_bb0065","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.neuroimage.2009.07.011","article-title":"Optimizing power to track brain degeneration in Alzheimer\u2019s disease and mild cognitive impairment with tensorbased morphometry: an ADNI study of 515 subjects","volume":"48","author":"Hua","year":"2009","journal-title":"Neuroimage"},{"issue":"Pt 4","key":"10.2515\/therapie\/2010057_bb0070","first-page":"1067","article-title":"MRI of hippocampal volume loss in early Alzheimer\u2019s disease in relation to ApoE genotype and biomarkers","volume":"132","author":"Schuff","year":"2009","journal-title":"Brain"},{"key":"10.2515\/therapie\/2010057_bb0075","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2010057_bb0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2010057_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12603-009-0036-7","article-title":"How can we recognize \"disease modification\" effects?","volume":"13","author":"Siemers","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.2515\/therapie\/2010057_bb0090","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch Neurol"},{"issue":"1","key":"10.2515\/therapie\/2010057_bb0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1468-1331.2009.02753.x","article-title":"Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe","volume":"17","author":"Hort","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.2515\/therapie\/2010057_bb0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00019442-200411000-00002","article-title":"Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia","volume":"12","author":"Dougall","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.2515\/therapie\/2010057_bb0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","article-title":"Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study","volume":"73","author":"Okello","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.2515\/therapie\/2010057_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12603-009-0046-5","article-title":"Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregat","volume":"13","author":"Wischik","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.2515\/therapie\/2010057_bb0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s12603-009-0049-2","article-title":"The validity of biomarkers as surrogate endpoints in Alzheimer\u2019s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)","volume":"13","author":"Gispen-de Wied","year":"2009","journal-title":"J Nutr Health Aging"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:39:52Z","timestamp":1554277192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0040595716307119"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010057","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}